TRPML modulators

A compound of Formula IIb-1 or IId:

• or a pharmaceutically acceptable salt thereof, wherein
• L1 is —C(O)—NR3—, —NR3—C(O)—, or an optionally substituted bivalent moiety selected from C1-6 alkylenyl, —NR3-C0-6 alkylenyl, —C(O)—C0-6 alkylenyl, —C1-6 alkylenyl-C(O)—, and —C1-6 alkylenyl-O—C(O)—;
• Z is 4- to 16-membered monocyclic or polycyclic heterocyclyl comprising 1 to 4 heteroatoms selected from N, O, and S, wherein Z is substituted with (R2)q;
• each Ra is independently H, halo, —CN, or an optionally substituted group selected from C1-6 aliphatic, —C3-6 cycloaliphatic, and —O—C1-6 aliphatic;
• each R2 is independently selected from halo, oxo, —CN, —OH, —O—R2a, —C(O)—R2a, —C(O)O—R2ª, and
• an optionally substituted group selected from —C1-6 aliphatic, —C6-12 aryl, and 5- to 12-membered monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms selected from N, O, and S;
• each R2a is independently H or an optionally substituted group selected from C1-6 aliphatic, C3-12 cycloaliphatic, and 4- to 12-membered monocyclic or bicyclic heterocyclyl comprising 1 to 4 heteroatoms selected from N, O, and S;
• each R3 is independently selected from H and optionally substituted-C1-6 aliphatic;
• each R5 is —N(R3)2 or an optionally substituted group selected from —C1-6 aliphatic, —P(O)(C1-6 aliphatic)2, —C3-12 cycloaliphatic, and 5- to 12-membered monocyclic or polycyclic heterocyclyl comprising 1 to 4 heteroatoms selected from N, O, and S;
• each R6 is independently selected from halo, —SF5, —S(O)—R5, S(O)2—R5, —S(O)(NH)—R5, —S(O)2—(NH)—R5, —S(O)—N(R5)2, —S(O)2—N(R5)2, —CN, —C(O)—NH(R5), —C(O)—N(R5)2, —P(O)(R5)2, —O—R5, or an optionally substituted group selected from —C1-6 aliphatic, −S—C1-6 aliphatic, —C0-6 alkylenyl —C(O)—R5, —C0-6 alkylenyl-C(O)O—R5, —C6-12 aryl, —C3-12 cycloaliphatic, and 4- to 7-membered monocyclic heterocyclyl comprising 1 to 4 heteroatoms selected from N, O, and S;
• m is 0, 1, 2, 3, or 4;
• and
• q is 2.